# Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions

> **NCT07251153** · PHASE1 · RECRUITING · sponsor: **Enyo Pharma** · enrollment: 40 (estimated)

## Conditions studied

- Healthy Adult Male and Female Volunteers

## Interventions

- **DRUG:** EYP651/Vonafexor low dose
- **DRUG:** EYP651/Vonafexor high dose
- **DRUG:** EYP651/CYP3A4 inhibitor
- **DRUG:** EYP651/Transporter substrate
- **DRUG:** EYP651/CYP2C8 and CYP2C9 substrate

## Key facts

- **NCT ID:** NCT07251153
- **Lead sponsor:** Enyo Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-28
- **Primary completion:** 2025-12-18
- **Final completion:** 2026-10-28
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07251153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07251153, "Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07251153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*